Status:
SUSPENDED
Pyridostigmine as Immunomodulator in People Living With HIV
Lead Sponsor:
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Conditions:
HIV-1-infection
CD4+ T Lymphocytopenia
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Human immunodeficiency virus (HIV) infection is characterized by persistent immune activation and a constant turnover of T cells. This leads to a precipitous fall in the number of T cells, as well as ...
Detailed Description
Human immunodeficiency virus (HIV) infection is a public health problem with enormous personal, and social losses. According to the National Mexican HIV/AIDS survey, more than 235,000 new cases of HIV...
Eligibility Criteria
Inclusion
- HIV-1 infected subjects 18 years of age or older
- Receiving stable ART for at least six months
- At least two undetectable viral load determinations in the previous six months
- Patient agrees to participate and signs informed consent
Exclusion
- Concomitant active infectious or neoplastic disease
- History of new AIDS-defining events in the previous six months
- If a participant is female, pregnancy or breast-feeding
- Exposure to an investigational agent, chemotherapy or radiotherapy within the previous 28 days
- Currently taking or planning to take treatment for Tuberculosis
- Being unable to follow or comply with the protocol interventions
- The participant is receiving immunosuppressive treatment, including corticosteroids
Key Trial Info
Start Date :
July 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2022
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT03312244
Start Date
July 1 2019
End Date
June 30 2022
Last Update
April 10 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
Mexico City, Tlalpan, Mexico, 14080